| Document |
Document Title |
|
WO/2005/000863A2 |
The present invention discloses compounds of formula (I), or pharmaceutically acceptables salts, esters, or prodrugs thereof, which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions co...
|
|
WO/2004/110255A2 |
The present invention relates to novel antineoplastic agents and cancer diagnostic agents that specifically target neoplastic cells via the GLUT transportation system. More specifically, the invention relates to conjugates of 2-deoxygl...
|
|
WO/2004/111070A1 |
A compound of formula (I) wherein the bond between carbon atoms 22 and 23 may be a single or a double bond; R1 is C1-C12alkyl, C3-C8cycloalkyl, or C2-C12alkenyl; R2 and R3 are, for example, independently of each other hydrogen, C1-C12alk...
|
|
WO/2004/108745A2 |
The present invention discloses compounds of formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions com...
|
|
WO/2004/108744A2 |
The present invention relates to novel azalides and azaketolides having antimicrobial activity, methods for their preparation, pharmaceutical compositions containing the compounds and methods of treating microbial infections with the com...
|
|
WO/2004/108746A2 |
The present invention discloses compounds of formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions com...
|
|
WO/2004/106355A1 |
Said addition salts have a molar ratio between azithromycin and citric acid such as to provide a pH comprised between 4.0 and 8.0 in a 10 % aqueous solution. The process for preparing said salts comprises: a) dissolving azithromycin in a...
|
|
WO/2004/106353A1 |
The present invention relates to a process for selective alkylation of macrolide and azalide derivatives comprising reacting an macrolide or azalide derivative having a vicinal hydroxyl system with diazoalkane of the formula: R-CHN2 wher...
|
|
WO/2004/106354A1 |
The present disclooure relates to new 11-O-alkyl macrolides and azalides and pharmaceutically acceptable salts and solvates thereof, and to pharmaceutical compositions thereof. The disclosure also relates to a process for the preparation...
|
|
WO/2004/101586A1 |
The present invention relates to 14- or 15-membered macrolides substituted at the 4' position of formula (I) and pharmaceutically acceptable derivatives thereof, to processes for their preparation and their use in therapy or prophylaxis ...
|
|
WO/2004/101585A1 |
The present invention relates to 14- or 15-membered macrolides substituted at the 4' position of formula (I) and pharmaceutically acceptable derivatives thereof, to processes for their preparation and their use in therapy or prophylaxis ...
|
|
WO/2004/101591A1 |
The present invention relates to the new 3-decladinosyl derivatives of 9a-N-carbamoyland 9a-N-thiocarbamoyl-9-deoxo-9-dihydro-9a-aza-9a-homoerythromy
cin A of the general formula (I), their pharmaceutically acceptable addition salts wi...
|
|
WO/2004/101588A1 |
The present invention relates to 14- or 15-membered macrolides substituted at the 4' position of formula (I) and pharmaceutically acceptable derivatives thereof, to processes for their preparation and their use in therapy or prophylaxis ...
|
|
WO/2004/101584A1 |
The present invention relates to 14- or 15-membered macrolides substituted at the 3-position of formula (I) and pharmaceutically acceptable derivatives thereof, to processes for their preparation and their use in therapy or prophylaxis o...
|
|
WO/2004/101592A1 |
A process for producing 9-deoxo-9-hydroxyerythromycin A 11,12-cyclic carbonate derivatives useful as an intermediate in the synthesis of novel erythromycin A derivatives, which comprises reacting a compound represented by the general for...
|
|
WO/2004/101589A1 |
The present invention relates to 14- or 15-membered macrolides substituted at the 4' position of formula (I) and pharmaceutically acceptable derivatives thereof, to processes for their preparation and their use in therapy or prophylaxis ...
|
|
WO/2004/101590A1 |
The present invention relates to 15-membered macrolides substituted at the 4' position of formula (I) and pharmaceutically acceptable derivatives thereof, to processes for their preparation and their use in therapy or prophylaxis of syst...
|
|
WO/2004/101587A1 |
The present invention relates to 14- or 15-membered macrolides substituted at the 4' position of formula (I) and pharmaceutically acceptable derivatives thereof, to processes for their preparation and their use in therapy or prophylaxis ...
|
|
WO/2004/099230A1 |
A monosaccharide compound of the formula (I), wherein R1 is hydrogen or lower alkyl; R2 is hydrogen or lower alkoxy; R3 is hydrogen or hydroxy; R4 is hydrogen, lower alkoxycarbonyl or hydroxymethyl; and (a) represents single bond or doub...
|
|
WO2004087729A9 |
The invention is directed to degradation products of azithromycin, methods for the preparation and identification of the degradation products which may be produced during storage and/or synthesis of azithromycin.
|
|
WO/2004/096822A2 |
Antimicrobial macrolide and ketolide compounds are provided having formulas (XII), as well as pharmaceutically acceptable salts, esters or prodrugs thereof; pharmaceutical compositions comprising such compounds; methods of treating bacte...
|
|
WO/2004/096823A2 |
Antimierobial ketolide compounds are provided having the formula (A), as well as pharmaceutically acceptable salts, esters or prodrugs thereof, pharmaceutical compositions comprising such compounds, methods of treating bacterial infectio...
|
|
WO/2004/094449A1 |
The present invention relates to new compounds represented by Formula (I); wherein M represents a macrolide subunit of the substructure II, Formula (II); L represents the chain of the substructure III, Formula (III); D represents the ste...
|
|
WO/2004/094446A1 |
It is intended to provide novel preventives/remedies for diseases caused by the growth of vascular smooth muscle, for example, re-occlusion occurring after a ballon-dilation treatment for cardiac coronary occlusion. Namely, vascular smoo...
|
|
WO/2004/092736A2 |
The invention relates to derivatives of azithromycin, processes for the manufacture thereof and pharmaceutical compositions thereof preferably together with azithromycin.
|
|
WO/2004/092192A1 |
The present invention relates to compounds of the following general formula: (I) wherein R1 and R2 are fatty acyl groups, a process to extract them from Mycobacterium tuberculosis, and their use in the treatment or the prophylaxis of tub...
|
|
WO/2004/089966A1 |
A method for preparing a heteroaryl 5-thio-β -D-aldohexopyranoside compound of the formula (III), which comprises reacting 5-thio-D-aldohexopyranose compound of the formula (I) with A-OH of the formula (II) in the presence of a phosphin...
|
|
WO/2004/089967A1 |
It is intended to provide heteroaryl 5-thio-β-D-glucopyranoside compounds represented by the following general formula which show an effect of inhibiting the activity of SGLT2, pharmaceutically acceptable salts thereof or hydrates of th...
|
|
WO/2004/087727A1 |
A fused heterocyclic derivative represented by the general formula (I) (wherein R1 is hydrogen, OH, etc.; R2 is hydrogen, halogeno, or alkyl; R3 and R4 each is hydrogen, OH, halogeno, etc.; Q is alkylene, etc.; ring A is aryl or heteroar...
|
|
WO/2004/087728A2 |
The present invention discloses compounds of formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions com...
|
|
WO/2004/083227A1 |
Azithromycin isopropanolate of the empirical formula azithromycin: [H20]x: [isopropanol]y is obtained from the crystallization of azithromycin in isopropanol and water. The x and y values is confirmed by single X-ray diffraction determin...
|
|
WO/2004/080391A2 |
This invention relates to novel macrolides, to the preparation of novel macrolides, to the use of such novel macrolides for preventing, treating, or ameliorating various conditions, and to the use of such novel macrolides as antibacteria...
|
|
WO/2004/078770A1 |
The invention provides a family of bifunctional heterocyclic compounds useful as antiinfective, anti-proliferative, anti-inflammatory, and prokinetic agents. The invention also provides methods of making the bifunctional heterocyclic c...
|
|
WO/2004/078771A1 |
A 2-fluoro-6-O-substituted ketolide derivative represented by the formula (I) or a pharmaceutically acceptable salt thereof. The compound has potent antibacterial activity against Haemophilus influenzae and erythromycin-resistant Pneumoc...
|
|
WO/2004/073658A2 |
Isoflavones are modified by esterification at one or more of the C4', C5, C6, and C7 positions to promote bioavailability, and especially to enhance solubility over the corresponding unesterified isoflavones. Preferred modifications prod...
|
|
WO/2004/074132A1 |
A method of packaging of azithromycin in a gas impermeable container which provides improved stability of azithromycin upon storage.
|
|
WO2004016632B1 |
Novel lincomycin derivatives are disclosed. These lincomycin derivatives exhibit antibacterial activity. As the compounds of the subject invention exhibit potent activities against bacteria, including gram positive organisms, they are us...
|
|
WO/2004/069852A1 |
What is described are a compound of the formula (I) Wherein A-B is -CH=CH- or -CH2-CH2-; n is 0 or 1; R1, is C1-C12alkyl, C3-C8cycloalkyl or C2-C12alkenyl; R2 and R3 for instance are either, (i) independently from each other for instance...
|
|
WO/2004/069854A1 |
The application relates to novel macrolides having antibacterial activity. The macrolides are represented by the formula (I) wherein the substituents have the meaning disclosed herein.
|
|
WO/2004/069853A1 |
What is described are a compound of the formula (I) wherein the bond of atoms C22 and C23 is a single or double bond; m is 0 or l; n is 0, 1 or 2; p is 0 or l; R1 is C1-C12-alkyl, C3-C8-cycloalkyl or C2-C12-alkenyl; R2 is for example H, ...
|
|
WO/2004/067542A1 |
A compound having a structure represented by the following general formula (I): (I) (A is a cyclic group, etc.; R1 and R2 each is alkyl, hydroxymethyl, etc.; and n is 1 or 2); or a pharmacologically acceptable salt or ester of the compou...
|
|
WO/2004/067534A1 |
A compound of the general formula (I) pesticidal compositions whose active compound is selected from these compounds and their tautomers; intermediates for the preparation of the said compounds of the formula (I), methods for the prepara...
|
|
WO/2004/066725A2 |
Disclosed are compounds of the formulain which nis0orl; X-Y is -CH=CH- or -CH2-CH2-; Z is -C(=O)-, -C(=S)- or -S02-; R1 is C1-C12alkyl, C3-C8cycloalkyl or C2-C12alkenyl; and R2 is R3-Z-, R3-O-Z-, R4 or -Z-N(R6)(R7); Q is O or -N-R5; R3 a...
|
|
WO/2004/067543A1 |
What is described are a compound of the formula (I) Wherein U is -N(R2)OR3 or -N+(O-)=C(RE)RZ); n is 0 or 1; X-Y is -CH=CH- or -CH2-CH2-; R1 is C1-C12alkyl, C3-C8cycloalkyl or C2-C12alkenyl; R2 and R3 are, for example; independently from...
|
|
WO/2004/064715A2 |
Isolated immunomodulatory (e.g. immunostimulatory) polyhydroxlated pyrrolizidine compounds having the formula (I), wherein R is selected from the group comprising hydrogen, straight or branched, unsubstituted or substituted, saturated or...
|
|
WO/2004/065402A1 |
The invention relates to derivatives of 9-ketospinosyn derivatives, which are substituted in the C-9 position by a radical =N-(O, NH or NRx)-Ry, to a method for the production thereof, and to their use for controlling animal pests.
|
|
WO/2004/062629A2 |
The invention provides novel apoptosis-inducing compounds that include isolated, purified isoapoptolidin, and selectively functionalized isoapoptolidin derivatives and stereoisomers thereof; selectively functionalized apoptolidin derivat...
|
|
WO/2004/057983A1 |
It is intended to provide a composition containing isoflavone which has a high purity in a natural state and yet is highly soluble in water without adding any solubilizers or subjecting to chemically modification. It is found out that a ...
|
|
WO/2004/058790A1 |
It is intended to provide a nitrogen-containing heterocyclic derivative which has an excellent effect of inhibiting human SGLT2 activity and is useful as a preventive or a remedy for diseases caused by hyperglycemia such as diabetes, dia...
|
|
WO/2004/056843A2 |
The application provides antibiotic 10-substituted 10-desmethyl macrolides. In a preferred embodiment the macrolides have an erythromycin basic structure according the formula, wherein the variable substituents have the meaning indicated...
|
